NCT03287960View on ClinicalTrials.gov

Setmelanotide for the Treatment of Leptin Receptor (LEPR) Deficiency Obesity

PHASE3CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

January 30, 2018

Primary Completion Date

September 25, 2020

Study Completion Date

September 25, 2020

Conditions
Leptin Receptor Deficiency Obesity
Interventions
DRUG

Setmelanotide

Once daily subcutaneous injection

DRUG

Placebo

Once daily subcutaneous injection

Trial Locations (6)

75013

Institute of Cardiometabolism and Nutrition / Pitié-Salpêtrière Hospital, Paris

97405

Hôpital Félix GUYON, Saint-Denis

L3P 7P3

Markham Stouffville Hospital, Markham

Unknown

University of Ulm, Ulm

Erasmus Medical Center, Rotterdam

CB2 0QQ

University of Cambridge Metabolic Research Laboratories, Cambridge

All Listed Sponsors
lead

Rhythm Pharmaceuticals, Inc.

INDUSTRY

NCT03287960 - Setmelanotide for the Treatment of Leptin Receptor (LEPR) Deficiency Obesity | Biotech Hunter | Biotech Hunter